OBJECTIVE: The opening of the mitochondrial permeability transition pore (mPTP) at the time of myocardial reperfusion is a critical determinant of cell death. Emerging studies suggest that suppression of mPTP opening may underlie the cardioprotection elicited by both ischemic preconditioning (IPC) and postconditioning (IPost). To further evaluate the role of the mPTP in cardioprotection, we hypothesized that hearts deficient in cyclophilin-D (CYP-D-/-), a key component of the mPTP, will be resistant to cardioprotection conferred by ischemic and pharmacological preconditioning and postconditioning. METHODS AND RESULTS: Male/female wild type or CYP-D-/- mice were subjected to 30 min of ischemia and 120 min of reperfusion. In wild type mice subjected to in vivo myocardial ischemia-reperfusion injury, a significant reduction in myocardial infarct size was observed with the following treatments (n>/=6/group; P<0.05): (1) IPC (28+/-4% vs. 46.2+/-4% in control); (2) Diazoxide (5 mg/kg) pre-treatment (26.4+/-3% vs. 54+/-10% in vehicle control); (3) IPost-1 or IPost-2, three or six 10-s cycles of ischemia-reperfusion (27.2+/-3% and 32+/-4%, respectively vs. 46.2+/-4% in control); (4) Bradykinin (40 mug/kg) (28.3+/-1% vs. 48+/-4% in vehicle control); (5) cyclosporin-A (10 mg/kg) (32.3+/-3% vs. 48+/-4% in vehicle control) (6) sanglifehrin-A (25 mg/kg) (29.3+/-3% vs. 48+/-4% in vehicle control). Interestingly, however, no infarct-limiting effects were demonstrated in CYP-D-/- mice with the same treatment protocols: (27.9+/-5% in control vs. 31.2+/-7% with IPC, 30.2+/-5% with IPost-1, 24.7+/-8% with IPost-2; 30.1+/-4% in vehicle control vs. 26.4+/-7% with diazoxide; 24.6+/-4% in vehicle control vs. 24.9+/-5% with bradykinin, 26.8+/-7% with cyclosporin-A, 32.5+/-6% with sanglifehrin-A: n>/=6/group: P>0.05). CONCLUSION: This study demonstrates that the mPTP plays a critical role in the cardioprotection elicited by ischemic and pharmacological preconditioning and postconditioning.
OBJECTIVE: The opening of the mitochondrial permeability transition pore (mPTP) at the time of myocardial reperfusion is a critical determinant of cell death. Emerging studies suggest that suppression of mPTP opening may underlie the cardioprotection elicited by both ischemic preconditioning (IPC) and postconditioning (IPost). To further evaluate the role of the mPTP in cardioprotection, we hypothesized that hearts deficient in cyclophilin-D (CYP-D-/-), a key component of the mPTP, will be resistant to cardioprotection conferred by ischemic and pharmacological preconditioning and postconditioning. METHODS AND RESULTS: Male/female wild type or CYP-D-/- mice were subjected to 30 min of ischemia and 120 min of reperfusion. In wild type mice subjected to in vivo myocardial ischemia-reperfusion injury, a significant reduction in myocardial infarct size was observed with the following treatments (n>/=6/group; P<0.05): (1) IPC (28+/-4% vs. 46.2+/-4% in control); (2) Diazoxide (5 mg/kg) pre-treatment (26.4+/-3% vs. 54+/-10% in vehicle control); (3) IPost-1 or IPost-2, three or six 10-s cycles of ischemia-reperfusion (27.2+/-3% and 32+/-4%, respectively vs. 46.2+/-4% in control); (4) Bradykinin (40 mug/kg) (28.3+/-1% vs. 48+/-4% in vehicle control); (5) cyclosporin-A (10 mg/kg) (32.3+/-3% vs. 48+/-4% in vehicle control) (6) sanglifehrin-A (25 mg/kg) (29.3+/-3% vs. 48+/-4% in vehicle control). Interestingly, however, no infarct-limiting effects were demonstrated in CYP-D-/- mice with the same treatment protocols: (27.9+/-5% in control vs. 31.2+/-7% with IPC, 30.2+/-5% with IPost-1, 24.7+/-8% with IPost-2; 30.1+/-4% in vehicle control vs. 26.4+/-7% with diazoxide; 24.6+/-4% in vehicle control vs. 24.9+/-5% with bradykinin, 26.8+/-7% with cyclosporin-A, 32.5+/-6% with sanglifehrin-A: n>/=6/group: P>0.05). CONCLUSION: This study demonstrates that the mPTP plays a critical role in the cardioprotection elicited by ischemic and pharmacological preconditioning and postconditioning.
Authors: Jason E Kokoszka; Katrina G Waymire; Shawn E Levy; James E Sligh; Jiyang Cai; Dean P Jones; Grant R MacGregor; Douglas C Wallace Journal: Nature Date: 2004-01-29 Impact factor: 49.962
Authors: Zhi-Qing Zhao; Joel S Corvera; Michael E Halkos; Faraz Kerendi; Ning-Ping Wang; Robert A Guyton; Jakob Vinten-Johansen Journal: Am J Physiol Heart Circ Physiol Date: 2003-08 Impact factor: 4.733
Authors: Magdalena Juhaszova; Dmitry B Zorov; Suhn-Hee Kim; Salvatore Pepe; Qin Fu; Kenneth W Fishbein; Bruce D Ziman; Su Wang; Kirsti Ytrehus; Christopher L Antos; Eric N Olson; Steven J Sollott Journal: J Clin Invest Date: 2004-06 Impact factor: 14.808
Authors: Richdeep S Gill; Namdar Manouchehri; Tze-Fun Lee; Woo Jung Cho; Aducio Thiesen; Thomas Churchill; David L Bigam; Po-Yin Cheung Journal: Intensive Care Med Date: 2011-12-06 Impact factor: 17.440
Authors: Timothy R Matsuura; Jason A Bartos; Adamantios Tsangaris; Kadambari Chandra Shekar; Matthew D Olson; Matthias L Riess; Martin Bienengraeber; Tom P Aufderheide; Robert W Neumar; Jennifer N Rees; Scott H McKnite; Anna E Dikalova; Sergey I Dikalov; Hunter F Douglas; Demetris Yannopoulos Journal: Resuscitation Date: 2017-04-10 Impact factor: 5.262
Authors: Derek Z Wang; Allan W Jones; Walter Z Wang; Meifang Wang; Ronald J Korthuis Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-02-25 Impact factor: 4.052